Quarterly report pursuant to Section 13 or 15(d)

SETTLEMENT LIABILITY (Details Narrative)

v3.24.3
SETTLEMENT LIABILITY (Details Narrative) - USD ($)
$ in Thousands
Nov. 12, 2021
Nov. 13, 2024
Sep. 30, 2024
Dec. 31, 2023
Defined Benefit Plan Disclosure [Line Items]        
Long term debt     $ 18,650
REGENXBIO [Member]        
Defined Benefit Plan Disclosure [Line Items]        
Settlement liabilities, current $ 30,000      
Loss contingency settlement agreement terms (1) $20.0 million paid in November 2021 after execution of the Settlement Agreement, (2) $5.0 million on the first anniversary of the effective date of the Settlement Agreement (paid in November 2022), and (3) $5.0 million upon the earlier of (i) the third anniversary of the effective date of the Settlement Agreement or (ii) the closing of a Strategic Transaction, as defined in the Settlement Agreement.      
Debt Instrument, Interest Rate, Stated Percentage     9.60%  
REGENXBIO [Member] | Due in November 2024 [Member]        
Defined Benefit Plan Disclosure [Line Items]        
Long term debt     $ 4,900 $ 4,600
REGENXBIO [Member] | Due in November 2024 [Member] | Subsequent Event [Member] | Settlement Agreement [Member]        
Defined Benefit Plan Disclosure [Line Items]        
Long term debt   $ 5,000